Camurus Ab (CAMRF) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you Einar and hello everyone. Welcome to our fourth quarter earnings call and full year. As customary, please note our forward-looking statements, which I will assume that you have read. So moving over to the agenda, we will begin today's call with an introduction and business highlights, followed by financial, commercial and R&D pipeline reviews, before finishing off with the key takeaways and Q&A. With me in the call today is Anders Wadsholt, Chief Financial Officer, and Richard Jameson, Chief Commercial Officer. So a quick overview of CAMERAS. We are a rapidly growing commercial stage biopharmaceutical company, focused on developing and delivering innovative long-acting treatments for people living with serious and chronic illnesses. We have become a global leader in opioid dependence therapy with our products Buvidal and Brixadi. Our commercial reach covers Europe and Australia, and we are now expanding into the US as we gear up for upcoming product launches. At the core of our offerings is the fluid crystal technology, which supports advanced long acting injectable treatments and has proven successful through both our commercial and clinical results and collaborations. Alongside our meaningful investments in the R&D pipeline, We have maintained sustainable profitability since 2022, placing us in a good position for ongoing growth. Now turning to full year highlights. In 2025, we achieved several significant milestones that further strengthened our leadership in opioid dependence treatment and our ongoing expansion. We continue to build momentum with Buvilar and Brixadi, expanding the reach and impact across key regions. Importantly, the first of our new wave products, Oxyisa, received regulatory approval for acromegaly in both the EU and the UK. Supporting...